Literature DB >> 23846441

Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene.

Ming-Tseh Lin1, Li-Hui Tseng, Katie Beierl, Antony Hsieh, Michele Thiess, Nadine Chase, Amanda Stafford, Mark J Levis, James R Eshleman, Christopher D Gocke.   

Abstract

Internal tandem duplication (ITD) mutations of the FLT3 gene have been associated with a poor prognosis in acute myeloid leukemia. Detection of ITD-positive minor clones at the initial diagnosis and during the minimal residual disease stage may be essential. We previously designed a delta-PCR strategy to improve the sensitivity to 0.1% ITD-positive leukemia cells and showed that minor mutants with an allele burden of <1% can be clinically significant. In this study, we report on tandem duplication PCR (TD-PCR), a modified inverse PCR assay, and demonstrate a limit of detection of a few molecules of ITD mutants. The TD-PCR was initially designed to confirm ITD mutation of an amplicon, which was undetectable by capillary electrophoresis and was incidentally isolated by a molecular fraction collecting tool. Subsequently, TD-PCR detected ITD mutation in 2 of 77 patients previously reported as negative for ITD mutation by a standard PCR assay. TD-PCR can also potentially be applied to monitor minimal residual disease with high analytic sensitivity in a portion of ITD-positive acute myeloid leukemia patients. Further studies using TD-PCR to detect ITD mutants at diagnosis may clarify the clinical significance of those ITD mutants with extremely low allele burden.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846441      PMCID: PMC3744591          DOI: 10.1097/PDM.0b013e31828308a1

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  15 in total

1.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Authors:  Kathleen M Murphy; Mark Levis; Michael J Hafez; Tanya Geiger; Lisa C Cooper; B Douglas Smith; Donald Small; Karin D Berg
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

Review 2.  FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.

Authors:  Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Wolfgang Hiddemann; Torsten Haferlach
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

3.  Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific.

Authors:  D L Stirewalt; C L Willman; J P Radich
Journal:  Leuk Res       Date:  2001-12       Impact factor: 3.156

4.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells.

Authors:  A M Turner; N L Lin; S Issarachai; S D Lyman; V C Broudy
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

6.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

Authors:  S Meshinchi; W G Woods; D L Stirewalt; D A Sweetser; J D Buckley; T K Tjoa; I D Bernstein; J P Radich
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

7.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.

Authors:  Lee-Yung Shih; Chein-Fuang Huang; Jin-Hou Wu; Tung-Liang Lin; Po Dunn; Po-Nan Wang; Ming-Chung Kuo; Chang-Liang Lai; Hui-Chin Hsu
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Detection of minor clones with internal tandem duplication mutations of FLT3 gene in acute myeloid leukemia using delta-PCR.

Authors:  Katie Beierl; Li-Hui Tseng; Russell Beierl; Lisa Haley; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Diagn Mol Pathol       Date:  2013-03

10.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Authors:  Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

View more
  8 in total

Review 1.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

2.  Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.

Authors:  Jonathan C Dudley; Grzegorz T Gurda; Li-Hui Tseng; Derek A Anderson; Guoli Chen; Janis M Taube; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

Review 3.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

4.  False positives in multiplex PCR-based next-generation sequencing have unique signatures.

Authors:  Chad M McCall; Stacy Mosier; Michele Thiess; Marija Debeljak; Aparna Pallavajjala; Katie Beierl; Kristen L Deak; Michael B Datto; Christopher D Gocke; Ming-Tseh Lin; James R Eshleman
Journal:  J Mol Diagn       Date:  2014-07-11       Impact factor: 5.568

5.  Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Authors:  Michael R Grunwald; Li-Hui Tseng; Ming-Tseh Lin; Keith W Pratz; James R Eshleman; Mark J Levis; Christopher D Gocke
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-23       Impact factor: 5.742

6.  A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Jonathan C Dudley; Stacey Riel; Harrison Tsai; Gang Zheng; Keith W Pratz; Mark J Levis; Christopher D Gocke
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

Review 7.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

Review 8.  Molecular testing for acute myeloid leukemia.

Authors:  Dahui Qin
Journal:  Cancer Biol Med       Date:  2021-08-04       Impact factor: 4.248

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.